News First trial of Bundibugyo Ebola vaccine starts in UK Oxford University has launched what it says is the world's first phase I trial of a vaccine specifically designed to protect against Bundibugyo Ebola.
News Non-profit DNDi preps phase 3 trials for dengue antibody Non-profit DNDi has licensed a dengue therapy from India's SII, paving the way for a phase 3 trial in Malaysia, Thailand, and Brazil.
News Moderna's mResvia gets shot in the arm from EU contract A new EU procurement contract could give Moderna's RSV shot mResvia, which has struggled to gain traction in the market, a welcome boost.
News Trial of Bundibugyo Ebola drugs starts in DRC Patients are now being enrolled in a trial of two potential therapies for Bundibugyo Ebola, Mapp's MBP134 and Gilead's remdesivir, says WHO.
News UK's RQ Bio raises $115m for flu prevention drug RQ Bio has raised $115m for clinical trials of RQB01, a one-shot antibody designed for strain-agnostic protection against seasonal influenza viruses.
News FDA experts endorse Moderna's mRNA seasonal flu shot A unanimous endorsement from FDA advisors brings Moderna's RNA-based seasonal influenza vaccine a step closer to US approval.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.